Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYCO-002
- Development stage
- Preclinical
- Lead developer
- Mydecine Innovations Group
- Modality
- Small Molecules
01
Overview
MYCO-002 is a **novel MDMA-like entactogenic small molecule** being developed by **Mydecine** for the treatment of behavioral and mental health disorders. Based on company descriptions, it is intended to retain the prosocial and empathogenic therapeutic properties associated with MDMA while being engineered for a **reduced harm burden and improved safety profile**. Publicly available information indicates that the compound remains in **preclinical development**, and its exact chemical structure, molecular target profile, formulation, and clinical administration details have not been publicly disclosed.
- Other names
- MYCO-002MYCO002MYCO 002
Beyond the preview
Go deeper on MYCO-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYCO-002.